Concepedia

Yoshinao Kato

YK

7

Publications

320

Citations

7

H-Index

2001

Active since

Affiliations

Pfizer (Japan)(Current)

Meijo University

Kao Corporation (Japan)

Fujifilm (Japan)

Lion Corporation (Japan)

Yoshinao Kato is an author at Pfizer (Japan) specializing in medicine, pharmacology, and clinical chemistry.

Top concepts

Publications per year

2001–2015

7

Publications

7

Test battery with the human cell line activation test, direct peptide reactivity assay and DEREK based on a 139 chemical data set for predicting skin sensitizing potential and potency of chemicals

Osamu Takenouchi, Shiho Fukui, Kenji Okamoto et al. · Journal of Applied Toxicology · 2015 · 119 citations

, , +22

CJ-21,058, a New SecA Inhibitor Isolated from a Fungus.

Yutaka Sugie, SAE INAGAKI, Yoshinao Kato et al. · The Journal of Antibiotics · 2002 · 64 citations · Full text

Evaluation of combinations of <i>in vitro</i> sensitization test descriptors for the artificial neural network‐based risk assessment model of skin sensitization

Morihiko Hirota, Shiho Fukui, Kenji Okamoto et al. · Journal of Applied Toxicology · 2015 · 59 citations

, , +16

Thielavins as Glucose-6-phosphatase (G6Pase) Inhibitors: Producing Strain, Fermentation, Isolation, Structural Elucidation and Biological Activities.

Shinichi Sakemi, Hideo Hirai, Toshio Ichiba et al. · The Journal of Antibiotics · 2002 · 29 citations · Full text

Cytokine Production Inhibitors Produced by a Fungus, Oidiodendron griseum.

Katsuomi Ichikawa, Hideo Hirai, MASARU ISHIGURO et al. · The Journal of Antibiotics · 2001 · 17 citations · Full text

Rows per page

1–5 of 7